Search results for " bromide"

showing 10 items of 315 documents

Non-neuronal cholinergic system contributes to corticosteroid resistance in chronic obstructive pulmonary disease patients

2016

Background: Inhaled corticosteroid (ICS) with long-acting beta-2 agonists is a well-documented combination therapy for chronic obstructive pulmonary disease (COPD) based on its additive anti-inflammatory properties. By contrast, the recommendation of ICS in combination with long-acting muscarinic antagonist (LAMA) is not evidence-based. In this study, neutrophils obtained from COPD patients were used to compare the anti-inflammatory effects of aclidinium bromide (a long-acting muscarinic antagonist) with corticosteroids and their potential additive effect. Methods: Human sputum and blood neutrophils were isolated from healthy individuals ( n = 37), patients with stable COPD ( n = 52) and th…

Male0301 basic medicineNeutrophilsVesicular Acetylcholine Transport ProteinsAnti-Inflammatory AgentsDrug ResistanceNon-neuronal cholinergic systemPulmonary Disease Chronic Obstructive0302 clinical medicineMuscarinic acetylcholine receptorCOPDDrug SynergismAclidinium bromideMuscarinic acetylcholine receptor M2Middle AgedReceptors MuscarinicBronchodilator AgentsCorticosteroidDrug Therapy CombinationFemaleInflammation Mediatorsmedicine.drugPulmonary and Respiratory Medicinemedicine.medical_specialtyCombination therapymedicine.drug_classCorticosteroid resistanceMuscarinic AntagonistsFluticasone propionateCholine O-Acetyltransferase03 medical and health sciencesAclidinium bromideInternal medicinemedicineHumansCOPDAgedDose-Response Relationship Drugbusiness.industryResearchSputumMuscarinic antagonistmedicine.disease030104 developmental biologyEndocrinology030228 respiratory systemCase-Control StudiesFluticasonebusinessTropanesRespiratory Research
researchProduct

From Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines to Current Clinical Practice

2006

Background: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines have been promulgated to improve the management of chronic obstructive pulmonary disorder (COPD). Objective: To evaluate the extent to which the current therapeutic approach to COPD conforms to GOLD guidelines. Methods: This was a multicentre observational study of elderly COPD patients enrolled for acute care in general medicine or geriatric wards in tertiary hospitals in Italy in April 2002. Our series consisted of 471 patients >64 years of age consecutively admitted for acute exacerbations of COPD to wards participating in the study. Data describing drugs used prior to exacerbation and prescribed at …

MaleAgingmedicine.medical_specialtyDrug IndustryPharmacological therapyGuidelines as Topicurologic and male genital diseasesPulmonary Disease Chronic ObstructivePharmacotherapyOdds RatiomedicineHumansMulticenter Studies as TopicPharmacology (medical)Practice Patterns Physicians'Intensive care medicineAgedCOPDbusiness.industryRespiratory diseaseTiotropium bromidemedicine.diseaseDrug UtilizationObstructive lung diseaserespiratory tract diseasesClinical PracticeLung diseasePhysical therapyFemaleGuideline AdherenceAcute Exacerbation Tiotropium Methylxanthine Tiotropium Bromide Cumulative Illness Rate ScaleGeriatrics and Gerontologybusinessmedicine.drugDrugs & Aging
researchProduct

Guideline on management of the acute asthma attack in children by Italian Society of Pediatrics

2018

Abstract Background Acute asthma attack is a frequent condition in children. It is one of the most common reasons for emergency department (ED) visit and hospitalization. Appropriate care is fundamental, considering both the high prevalence of asthma in children, and its life-threatening risks. Italian Society of Pediatrics recently issued a guideline on the management of acute asthma attack in children over age 2, in ambulatory and emergency department settings. Methods The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was adopted. A literature search was performed using the Cochrane Library and Medline/PubMed databases, retrieving studies in Englis…

MaleAsthma; Asthma attack; Children; GuidelinesPediatricsReviewGuidelineCochrane LibraryIpratropium bromidePediatricsSeverity of Illness Index0302 clinical medicineAnti-Asthmatic AgentsChildChildrenSocieties MedicalPediatriclcsh:RJ1-570PrognosisBronchodilator AgentsEpinephrineTreatment OutcomeInhalationItalyChild PreschoolAmbulatoryAdministrationCombinationPractice Guidelines as TopicDrug Therapy CombinationFemaleHumanmedicine.drugmedicine.medical_specialtyAdolescentPrognosiAsthma attackMEDLINEGuidelinesRisk Assessment03 medical and health sciencesDrug Therapy030225 pediatricsMedicalAdministration InhalationmedicineAnti-Asthmatic AgentHumansAsthma; Asthma attack; Children; Guidelines; Administration Inhalation; Adolescent; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child; Child Preschool; Drug Therapy Combination; Female; Humans; Italy; Male; Pediatrics; Prognosis; Risk Assessment; Severity of Illness Index; Societies Medical; Treatment Outcome; Practice Guidelines as TopicPreschoolBronchodilator AgentAsthmabusiness.industrylcsh:PediatricsEmergency departmentGuidelinemedicine.diseaseAsthma030228 respiratory systemPediatrics Perinatology and Child HealthbusinessSocieties
researchProduct

Increased acetone exhalation induced by metabolites of halogenated C1 and C2 compounds.

1982

Rats were exposed, in a closed desiccator jar chamber, to concentrations of various halogenated C1 and C2 compounds at which the metabolizing capacities were saturated (Vmax conditions). Within the exposure period of 50 h concentrations of the xenobiotic and of exhaled acetone were monitored in the gas phase of the system. The quantitative extent of acetone exhalation was dependent on the individual compound examined. Acetone exhalation was stimulated in presence of vinyl chloride, vinyl bromide, vinyl fluoride, vinylidene fluoride, cis- and trans-1,2-dichloroethylene, trichloroethylene, perchloroethylene, methylene chloride, chloroform, carbon tetrachloride and 1,1,2-trichloroethane. No st…

MaleChloroformChromatographyTrichloroethyleneVinyl bromideHydrocarbons HalogenatedHealth Toxicology and MutagenesisRats Inbred StrainsGeneral MedicineToxicologyChlorideVinyl chlorideRatsAcetonechemistry.chemical_compoundchemistryBreath TestsAcetonemedicineOrganic chemistryAnimalsFluorideVinyl fluoridemedicine.drugArchives of toxicology
researchProduct

Inhalation pharmacokinetics based on gas uptake studies. IV. The endogenous production of volatile compounds.

1983

A pharmacokinetic description of production, distribution and metabolism of endogenous volatile compounds is presented. This description uses the "gas uptake model" of a closed recirculated atmosphere in which experimental animals are exposed. As an example, the production rates of acetone, under different conditions of stimulation by xenobiotics, are calculated from published experimental data. The theoretical descriptions may serve as a basis for treating the problem of hydrocarbon exhalation in toxicological experiments with compounds eliciting lipid peroxidation.

MaleChromatographyInhalationTrichloroethyleneVinyl bromideHealth Toxicology and MutagenesisEndogenyRats Inbred StrainsGeneral MedicineMetabolismToxicologyModels BiologicalRatsAcetonechemistry.chemical_compoundKineticschemistryPharmacokineticsAcetoneOrganic chemistryAnimalsGasesVolatilizationXenobioticArchives of toxicology
researchProduct

Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use

2013

SummaryBackgroundIndacaterol is a once-daily, long-acting β2-agonist bronchodilator that improves dyspnoea and health status in patients with moderate-to-severe COPD. While its bronchodilator effects have been shown to be maintained in different patient subgroups, effects on clinical outcomes in certain subgroups are not yet defined.MethodsPost-hoc analysis of pooled clinical study data to investigate efficacy and safety of indacaterol compared with placebo and other long-acting bronchodilators (formoterol, salmeterol, open-label tiotropium) in patient subgroups defined by COPD severity (GOLD stage II or III; n = 4082) and ICS use at baseline (no/yes; n = 4088). Efficacy outcomes were troug…

MaleCopd patientsVital CapacityQuinolonesSeverity of Illness IndexPulmonary Disease Chronic ObstructiveForced Expiratory VolumeFormoterol FumarateBronchodilatorFormoterolSalmeterolSalmeterol XinafoateRandomized Controlled Trials as TopicIndacaterolCOPDMiddle AgedBronchodilator AgentsTreatment OutcomeEthanolaminesAnesthesiaIndansDrug Therapy CombinationFemaleSalmeterolmedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classScopolamine DerivativesPlaceboDrug Administration ScheduleInternal medicineAdministration InhalationmedicineHumansCOPDAlbuterolTiotropium BromideAdrenergic beta-2 Receptor AgonistsGlucocorticoidsAgedbusiness.industryTiotropiummedicine.diseaserespiratory tract diseasesDyspneaLong actingIndacaterolFormoterolbusinessRespiratory Medicine
researchProduct

Increased levels of Th17 cells are associated with non-neuronal acetylcholine in COPD patients.

2014

T-lymphocytes, including Th17-cells and T-cells expressing acetylcholine (ACh), are key components of systemic inflammation in chronic obstructive pulmonary disease (COPD). We investigated whether ACh promotes Th17 cells in COPD. ACh, IL-17A, IL-22, RORγt, FOXP3 expression and AChIL-17A, AChIL-22, AChRORγt coexpression was evaluated in peripheral blood mononuclear cells (PBMC) from COPD patients (n=16), healthy smokers (HS) (n=12) and healthy control subjects (HC) (n=13) (cultured for 48 h with PMA) by flow cytometry. Furthermore, we studied the effect of Tiotropium (Spiriva®) (100 nM) and Olodaterol (1nM) alone or in combination, and of hemicholinium-3 (50 μM) on AChIL-17A, AChIL-22, AChRO…

MaleImmunologyIntracellular SpaceScopolamine DerivativesPharmacologySystemic inflammationPeripheral blood mononuclear cellCholinergic AntagonistsFlow cytometrychemistry.chemical_compoundPulmonary Disease Chronic ObstructiveRAR-related orphan receptor gammaRisk FactorsmedicineImmunology and AllergyHumansTiotropium BromideAgedAged 80 and overCOPDmedicine.diagnostic_testbusiness.industryInterleukinsOlodaterolInterleukin-17FOXP3Forkhead Transcription FactorsHematologyMiddle AgedNuclear Receptor Subfamily 1 Group F Member 3medicine.diseaseAcetylcholineBenzoxazineschemistryLeukocytes MononuclearTh17 CellsFemalemedicine.symptombusinessAcetylcholinemedicine.drugImmunobiology
researchProduct

In vitro anticholinergic drugs affect CD8+ peripheral blood T-cells apoptosis in COPD

2011

Novel pharmacological strategies are aimed at the resolution of systemic inflammation in COPD potentiating peripheral blood T-cell (PBT-cell) apoptosis. Although muscarinic acetylcholine receptors (mAChRs) M(3) and choline-acetyltransferase (ChAT) participate in the airway inflammation of COPD, their role in PBT-cell apoptosis remains unexplained. We evaluated in PBT-cells from COPD patients, smoker (S) and control (C) subjects: (1) apoptosis (by annexin V binding), (2) mAChR M(3) and ChAT expression, acetylcholine (ACh)-binding; (3) choline levels in serum and PBT-cells extracts. We tested the effects of Tiotropium (Spiriva(®)) and hemicholinium-3 (HCh-3) on apoptosis, NFκB pathway, caspas…

MaleImmunologyScopolamine DerivativesApoptosisCD8-Positive T-LymphocytesPharmacologySystemic inflammationCholinergic AntagonistsCholineCholine O-AcetyltransferasePulmonary Disease Chronic ObstructiveAnnexinMuscarinic acetylcholine receptormedicineHumansImmunology and AllergyLymphocyte CountTiotropium BromideCaspaseAgedReceptor Muscarinic M3Caspase 8COPDbiologyCaspase 3Systemic inflammation Non-neuronal components of cholinergic system Caspases NF B pathwaybusiness.industryNF-kappa BHematologyTiotropium bromideMiddle Agedmedicine.diseaserespiratory tract diseasesEnzyme ActivationApoptosisbiology.proteinFemalemedicine.symptombusinessAcetylcholineProtein BindingSignal Transductionmedicine.drugImmunobiology
researchProduct

Indacaterol vs tiotropium in COPD patients classified as GOLD A and B

2015

SummaryIntroductionAccording to current GOLD strategy, patients with COPD classified as groups A and B may be treated with inhaled bronchodilators, either long-acting β2-agonist (LABA) or long-acting muscarinic antagonist (LAMA). However, there is little guidance on which class of agent is preferred and a lack of prospective data to differentiate the two.MethodsIn this study, we performed post-hoc analyses of pooled data from two prospective, controlled clinical trials comparing the LABA indacaterol and LAMA tiotropium in 1422 patients with moderate airflow limitation and no history of exacerbations in the previous year. This population fits the definitions of GOLD A and B groups and could …

MalePulmonary and Respiratory MedicineEfficacyPopulationINDEXESQuinolonesOBSTRUCTIVE PULMONARY-DISEASEPulmonary Disease Chronic ObstructiveHumansMedicineCOPDCOHORTProspective StudiesGOLDTiotropium BromideeducationDYSPNEAIndacateroleducation.field_of_studyCOPDDose-Response Relationship Drugbiologybusiness.industryTiotropiumONCE-DAILY INDACATEROLMuscarinic antagonistForced Expiratory Flow RatesBaseline Dyspnea IndexMiddle AgedLamabiology.organism_classificationmedicine.diseaseBronchodilator Agentsrespiratory tract diseasesClinical trialTreatment OutcomeAnesthesiaIndansCohortIndacaterolFemalebusinessCLINICAL METHODSFollow-Up Studiesmedicine.drugRespiratory Medicine
researchProduct

Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with mod…

2015

Background QVA149 is a once-daily (o.d.) inhaled dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium for the treatment of COPD. The QUANTIFY study compared QVA149 with a free-dose bronchodilator combination of tiotropium plus formoterol (TIO+FOR) in improving health-related quality of life (HRQoL) of patients with COPD. Methods This multicentre, blinded, triple-dummy, parallel-group, non-inferiority study randomised patients aged ≥40 years with moderate-to-severe COPD (post-bronchodilator forced expiratory volume in 1 s (FEV1) ≥30% to <80% predicted) to QVA149 110/50 µg o.d. or TIO 18 µg o…

MalePulmonary and Respiratory MedicineVital capacitymedicine.drug_classChronic Obstructive Pulmonary DiseaseVital CapacityScopolamine DerivativesQuinolonesCOPD PharmacologyDrug Administration SchedulePulmonary Disease Chronic ObstructiveFEV1/FVC ratioDouble-Blind MethodQuality of lifeForced Expiratory VolumeFormoterol FumarateBronchodilatorHumansMedicine1506Tiotropium BromideAdrenergic beta-2 Receptor AgonistsAgedCOPDbusiness.industryMiddle Agedmedicine.diseaseGlycopyrrolateBronchodilator Agentsrespiratory tract diseasesDrug CombinationsTreatment OutcomeEthanolaminesBronchodilator AgentsAnesthesiaIndansQuality of LifeIndacaterolFemaleFormoterolbusinessmedicine.drugThorax
researchProduct